PLSE Stock Overview
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pulse Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.86 |
| 52 Week High | US$13.62 |
| 52 Week Low | US$3.78 |
| Beta | 1.7 |
| 1 Month Change | -19.67% |
| 3 Month Change | -18.72% |
| 1 Year Change | 17.67% |
| 3 Year Change | -67.02% |
| 5 Year Change | -39.82% |
| Change since IPO | 64.51% |
Recent News & Updates
Recent updates
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Dec 25
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Sep 04Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Mar 08Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO
Sep 20Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky
Apr 04Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?
Oct 29Pulse Biosciences gets Health Canada approval for CellFX System
Jun 09Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?
Mar 31Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
Feb 24Pulse Biosciences establishes at-the-market equity program
Feb 04What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?
Jan 20Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication
Jan 12We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Dec 16
Shareholder Returns
| PLSE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -8.2% | 1.4% | 1.2% |
| 1Y | 17.7% | -0.7% | 24.7% |
Return vs Industry: PLSE exceeded the US Medical Equipment industry which returned -0.7% over the past year.
Return vs Market: PLSE underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| PLSE volatility | |
|---|---|
| PLSE Average Weekly Movement | 9.8% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PLSE's share price has been volatile over the past 3 months.
Volatility Over Time: PLSE's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 61 | Kevin Danahy | www.pulsebiosciences.com |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. Fundamentals Summary
| PLSE fundamental statistics | |
|---|---|
| Market cap | US$378.85m |
| Earnings (TTM) | -US$42.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.0x
P/E RatioIs PLSE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLSE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.21m |
| Earnings | -US$42.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PLSE perform over the long term?
See historical performance and comparison